Kangji Medical Holdings (HKSE:09997) ROCE % : 16.10% (As of Dec. 2023)

View and export this data going back to 2020. Start your Free Trial

What is Kangji Medical Holdings ROCE %?

ROCE % measures how well a company generates profits from its capital. It is calculated as EBIT divided by Capital Employed, where Capital Employed is calculated as Total Assets minus Total Current Liabilities. Kangji Medical Holdings's annualized ROCE % for the quarter that ended in Dec. 2023 was 16.10%.

Kangji Medical Holdings ROCE % Historical Data

The historical data trend for Kangji Medical Holdings's ROCE % can be seen below:

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

* Premium members only.

Kangji Medical Holdings ROCE % Chart

Kangji Medical Holdings Annual Data

Trend

Dec17

Dec18

Dec19

Dec20

Dec21

Dec22

Dec23

ROCE %

Get a 7-Day Free Trial

76.50

18.04

17.46

15.23

14.80

Kangji Medical Holdings Semi-Annual Data
	Dec17	Dec18	Jun19	Dec19	Jun20	Dec20	Jun21	Dec21	Jun22	Dec22	Jun23	Dec23
ROCE %	Get a 7-Day Free Trial							19.02	10.85	18.92	14.06	16.10

Kangji Medical Holdings ROCE % Calculation

Kangji Medical Holdings's annualized ROCE % for the fiscal year that ended in Dec. 2023 is calculated as:

ROCE %	=	EBIT	/	( (Capital Employed	+	Capital Employed)	/ count )
		(A: Dec. 2023 )		(A: Dec. 2022 )		(A: Dec. 2023 )
	=	EBIT	/	( ( (Total Assets - Total Current Liabilities)	+	(Total Assets - Total Current Liabilities) )	/ count )
		(A: Dec. 2023 )		(A: Dec. 2022 )		(A: Dec. 2023 )
	=	646.454	/	( ( (4450.009 - 171.604)	+	(4663.674 - 208.719) )	/ 2 )
	=	646.454	/	( (4278.405	+	4454.955)	/ 2 )
	=	646.454	/	4366.68
	=	14.80 %

Kangji Medical Holdings's ROCE % of for the quarter that ended in Dec. 2023 is calculated as:

ROCE %	=	EBIT ⁽¹⁾	/	( (Capital Employed	+	Capital Employed)	/ count )
		(Q: Dec. 2023 )		(Q: Jun. 2023 )		(Q: Dec. 2023 )
	=	EBIT	/	( ( (Total Assets - Total Current Liabilities)	+	(Total Assets - Total Current Liabilities) )	/ count )
		(Q: Dec. 2023 )		(Q: Jun. 2023 )		(Q: Dec. 2023 )
	=	696.888	/	( ( (4597.651 - 397.728)	+	(4663.674 - 208.719) )	/ 2 )
	=	696.888	/	( ( 4199.923	+	4454.955 )	/ 2 )
	=	696.888	/	4327.439
	=	16.10 %

(1) Note: The EBIT data used here is two times the semi-annual (Dec. 2023) EBIT data.

Kangji Medical Holdings (HKSE:09997) ROCE % Explanation

ROCE % can be especially useful when comparing the performance of capital-intensive companies. Unlike ROE %, which indicates the profitability of Shareholders Equity, ROCE % also considers long-term debt in Capital Employed. This can be helpful when analyzing companies with significant debt, as the result is neutralized by taking debt into consideration.

Generally speaking, a higher ROCE % indicates a stonger profitability for a company. Moreover, it is important to look at the ratio from a long term perspective. Investors tend to favor companies with stable and rising ROCE % trend over those with volatile ones.

Kangji Medical Holdings ROCE % Related Terms

Thank you for viewing the detailed overview of Kangji Medical Holdings's ROCE % provided by GuruFocus.com. Please click on the following links to see related term pages.

Kangji Medical Holdings (HKSE:09997) Business Description

Industry

GURUFOCUS.COM » STOCK LIST » Healthcare » Medical Devices & Instruments » Kangji Medical Holdings Ltd (HKSE:09997) » Definitions » ROCE %

Comparable Companies

Traded in Other Exchanges

50J:Germany

Address

No. 1668 Chunjiang East Road, Tonglu Economic Development Zone, Zhejiang Province, Hangzhou, CHN

Website

https://www.kangjimedical.com

Kangji Medical Holdings Ltd is engaged in the production and sales of minimally invasive surgical instruments and accessories. The company offers a product portfolio to provide physicians and hospitals with one-shop and tailored surgical solutions for four surgical specialties OBGYN, general surgery, urology, and thoracic surgery. It manufactures and sells both disposable and reusable products. Its product portfolio includes disposable trocars, polymer ligation clips, disposable electrocoagulation forceps, and reusable trocar and forceps. It derives the majority of its revenue from Mainland China.

Kangji Medical Holdings (HKSE:09997) Headlines

No Headlines